Further Information
Campath^® (alemtuzumab) is approved as a single agent for the treatment of B-cell chronic lymphocytic leukaemia (B-CLL). It binds to the CD52 antigen, which is present on the surface of B and T lymphocytes and other cells. After binding to the CD52 antigen present on the surface of leukaemic cells, it destroys them.

Campath® is also in Phase III development for multiple sclerosis and the programme has been granted Fast Track status by the FDA. A four-year review of a Phase II study, presented at the American Academy of Neurology annual meeting, showed that an estimated 71% of alemtuzumab treated patients were free of clinically-active disease, compared to 35% of patients taking Rebif® (interferon beta-1a). Two Phase III trials are fully enrolled. One is comparing Campath^® to Rebif^® as a first-line therapy for patients with relapsing-remitting MS, and the second patients who have continued to experience relapse episodes while on currently available disease modifying therapies.

Data are anticipated in 2011, with potential approval in 2012.